MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Interest Expense 2011-2026 | QTNT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.72 M | 2.2 M | -6.94 M | 2.37 M | -1.11 M | 3.5 M | -4.06 M | -197 K | 11 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 M | -6.94 M | -167 K |
Quarterly Interest Expense Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 M | 1.01 M | -19.6 M | - | -3.51 M | 677 K | 4.18 M | 9.5 M | 617 K | 192 K | 5 M | 233 K | 1.89 M | 1.89 M | -1.24 M | 952 K | -1.54 M | -1.54 M | -468 K | - | 33 K | 565 K | 880 K | - | -4.57 M | -1.89 M | 2.68 M | - | 305 K | -987 K | -1.29 M | - | 130 K | -1.49 M | 534 K | - | -45 K | -83 K | 77 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.6 M | -19.6 M | 416 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
81 M | $ 110.31 | -2.79 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
14.3 M | $ 289.46 | -3.69 % | $ 17.2 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
8.55 M | $ 13.12 | -3.14 % | $ 3.73 B | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
177 M | $ 62.39 | -5.61 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.59 | -4.49 % | $ 655 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 158.5 | -4.02 % | $ 7.86 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.05 | -1.56 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 8.71 | -4.86 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.08 | -1.6 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
-1 K | $ 25.69 | -5.55 % | $ 33.3 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.68 | -4.55 % | $ 889 M | USA |
 |
Syneos Health
SYNH
|
79.3 M | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
249 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
-233 K | $ 0.19 | -0.08 % | $ 18.3 M |  Singapore |
|
Biodesix
BDSX
|
8.26 M | $ 14.29 | -2.16 % | $ 1.85 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 108.63 | -5.38 % | $ 5.08 B | USA |
 |
Biomerica
BMRA
|
367 | $ 1.99 | -5.52 % | $ 4.57 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.61 | -10.22 % | $ 179 M | China |
 |
Bioventus
BVS
|
-1.45 M | $ 8.93 | -3.62 % | $ 595 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
1.19 M | - | - | $ 1.49 B | USA |